Literature DB >> 1801651

A review of the recent progress in treatment of patients with diffuse panbronchiolitis associated with Pseudomonas aeruginosa infection in Japan.

H Tanimoto1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1801651     DOI: 10.1159/000420303

Source DB:  PubMed          Journal:  Antibiot Chemother (1971)        ISSN: 0066-4758


× No keyword cloud information.
  7 in total

1.  Additive effect of continuous low dose ofloxacin on erythromycin therapy for sinobronchial syndrome.

Authors:  M Fujimura; Y Ishiura; M Saito; K Shibata; M Nomura; Y Nakatsumi; T Matsuda
Journal:  Drugs       Date:  1995       Impact factor: 9.546

2.  Diffuse panbronchiolitis and cystic fibrosis: East meets West.

Authors:  N Høiby
Journal:  Thorax       Date:  1994-06       Impact factor: 9.139

3.  The effects of azithromycin on patients with diffuse panbronchiolitis: a retrospective study of 29 cases.

Authors:  Ding Hui; Fen Yan; Ru-Hua Chen
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

4.  Essential role of transcription factor nuclear factor-kappaB in regulation of interleukin-8 gene expression by nitrite reductase from Pseudomonas aeruginosa in respiratory epithelial cells.

Authors:  N Mori; K Oishi; B Sar; N Mukaida; T Nagatake; K Matsushima; N Yamamoto
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

5.  Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis.

Authors:  Lisa Saiman; Yunhua Chen; Pablo San Gabriel; Charles Knirsch
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

6.  Role of interleukin-8 (IL-8) and an inhibitory effect of erythromycin on IL-8 release in the airways of patients with chronic airway diseases.

Authors:  K Oishi; F Sonoda; S Kobayashi; A Iwagaki; T Nagatake; K Matsushima; K Matsumoto
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

7.  Azithromycin in the extremely low birth weight infant for the prevention of bronchopulmonary dysplasia: a pilot study.

Authors:  Hubert O Ballard; Michael I Anstead; Lori A Shook
Journal:  Respir Res       Date:  2007-06-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.